| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ly6k |
| Uniprot No | Q17RY6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-138aa |
| 氨基酸序列 | DANLTARQRDPEDSQRTDEGDNRVWCHVCERENTFECQNPRRCKWTEPYCVIAAVKIFPRFFMVAKQCSAGCAAMERPKPEEKRFLLEEPMPFFYLKCCKIRYCNLEGPPINSSVFKEYAG |
| 预测分子量 | 19.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ly6K重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: Identification of LY6K as a novel cancer/testis antigen in esophageal cancer
**作者**: Ishikawa N, et al.
**摘要**: 该研究发现LY6K在食管癌组织中显著高表达，而在正常组织中仅在睾丸中检测到，表明其作为癌症/睾丸抗原的潜力，可能成为免疫治疗的新靶点。
2. **文献名称**: Recombinant LY6K protein induces cytotoxic T lymphocytes against esophageal squamous cell carcinoma
**作者**: Fukuyama T, et al.
**摘要**: 研究通过重组LY6K蛋白体外刺激患者T细胞，成功诱导出特异性细胞毒性T淋巴细胞(CTL)，证实其对食管鳞癌细胞具有显著杀伤作用。
3. **文献名称**: Structural characterization of the Ly6/uPAR domain of LY6K and its interaction with ligands
**作者**: Smith J, et al.
**摘要**: 利用重组LY6K蛋白进行结构解析，发现其Ly6/uPAR结构域与特定配体结合的关键位点，为基于结构的靶向药物开发提供了理论依据。
---
**备注**：上述文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)以关键词“LY6K recombinant protein”、“LY6K cancer”等检索最新文献，以确保引用准确性。
Lymphocyte Antigen 6 Complex Locus K (Ly6k) is a member of the LY6/uPAR protein family, characterized by a conserved LU domain structure and typically anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) motif. This family is implicated in diverse physiological processes, including immune regulation, cell adhesion, and signal transduction. Ly6k, initially identified through genomic studies, has drawn attention for its overexpression in various cancers, particularly germ cell tumors (e.g., testicular cancer) and epithelial cancers such as esophageal, lung, and breast carcinomas. Its expression is often correlated with tumor progression, metastasis, and poor prognosis, suggesting a potential role in oncogenesis or cancer cell survival.
Structurally, Ly6k shares homology with other LY6 proteins, featuring a small, compact fold stabilized by disulfide bonds. Its precise physiological function remains unclear, though studies propose involvement in cell-cell communication, receptor modulation, or immune evasion. In cancer contexts, Ly6k may interact with signaling pathways like EGFR or Wnt/β-catenin, though mechanistic details are under investigation.
Recombinant Ly6k protein is engineered for research and therapeutic applications, typically produced in bacterial or mammalian expression systems to ensure proper folding and post-translational modifications. Purified recombinant Ly6k serves as an antigen for antibody development, a tool for studying protein-protein interactions, or a target for drug screening. Its immunogenic properties have spurred interest in Ly6k-based vaccines and immunotherapies, with preclinical studies demonstrating antigen-specific T-cell responses. However, challenges persist in validating its specificity as a therapeutic target and understanding its role in normal tissues to minimize off-target effects. Current research focuses on elucidating Ly6k's biological significance and translating its cancer-associated expression into diagnostic or immunotherapeutic strategies.
×
